Global Mycoplasma Testing

Mycoplasma Testing Comprehensive Study by Type (Instruments, Kits & Reagents (Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other), Services), Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others), Technology (ELISA (Enzyme-linked Immunosorbent Assay), Microbial Culture Techniques, PCR (Polymerase Chain Reaction), Indirect Assay, Enzymatic Methods, Direct Assay), End User (Academic Research Institutions and Organizations, Pharmaceutical & Biotechnology Companies, Cell Banks, Contract Service Laboratories, Government Agencies) Players and Region - Global Market Outlook to 2030

Mycoplasma Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 12.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Mycoplasma Testing
The increasing incidence of mycoplasma contamination, as well as increasing research and development activities, will help to boost global Mycoplasma Testing market in the forecasted period. Mycoplasma testing is mainly used to help determine if Mycoplasma pneumonia is the cause of a respiratory tract infection. Also, It used to help diagnose a systemic infection that is thought to be due to mycoplasma. In the biotechnology sector, they are growing used for drug screening and development, and large-scale manufacturing of biological compounds.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Billion)
CAGR12.5%


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Mycoplasma Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Thermo Fisher Scientific Inc. (United States), Charles River Laboratories International, Inc. (United States), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (United States), Bionique Testing Laboratories, Inc. (United States), InvivoGen (United States) and PromoCell GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are WuXi AppTec (United States), Norgen Biotek Corp. (Canada), Agilent Technologies (United States), Biotools, B & M Labs, S.A (Spain), Eurofins Scientific (Luxembourg), Gibraltar Laboratories (United States), GeneCopoeia, Inc. (United States), GenBio (Canada), Hylabs (Israel), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (United States), Sartorius AG (Germany), Savyon Diagnostics (Israel) and ScienCell Research Laboratories, Inc. (Canada).

Segmentation Overview
AMA Research has segmented the market of Global Mycoplasma Testing market by Type (Instruments, Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other] and Services), Application (Cell Line Testing, Virus Testing, End of Production Cells Testing and Others) and Region.



On the basis of geography, the market of Mycoplasma Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Technology, the sub-segment i.e. ELISA (Enzyme-linked Immunosorbent Assay) will boost the Mycoplasma Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Academic Research Institutions and Organizations will boost the Mycoplasma Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Demand Due to Cell Culture Contamination and Huge R&D Investments in Life Sciences

Market Growth Drivers:
Government Support for Pharma as well as Biotech Industry and Technological Advancement in Mycoplasma Testing

Challenges:
Dearth Of Skilled Workforce

Restraints:
Stringent Government Regulations and Growing Concern Regarding High Degree of Consolidation Acts for New Entrants

Opportunities:
Huge Potential for Pharmaceuticals Outsourcing

Market Leaders and their expansionary development strategies
On 14th March 2019, Lonza Expands Mycoplasma Detection Portfolio with New Luminometer Designed to Accelerate and Simplify Testing. The expansion of the portfolio with the new Lucetta™ 2 Luminometer establishes Lonza as the leading provider of fast, simple and accurate mycoplasma detection solutions,
On 10th July 2018, ATCC, the premier global biological materials resource and standards organization and the leading supplier of authenticated cells and advanced cell models, has announced the availability of its new PCR-based service to detect mycoplasma contamination in cell cultures.


Key Target Audience
Mycoplasma Testing Instrument Manufacturers, Mycoplasma Testing Instrument Vendors, Distributors, and Service Providers, Pharmaceutical and Biotechnology Companies, Academic Research Institutes Related to Mycoplasma Testing and Contract Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Instruments
  • Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other]
  • Services
By Application
  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others
By Technology
  • ELISA (Enzyme-linked Immunosorbent Assay)
  • Microbial Culture Techniques
  • PCR (Polymerase Chain Reaction)
  • Indirect Assay
  • Enzymatic Methods
  • Direct Assay

By End User
  • Academic Research Institutions and Organizations
  • Pharmaceutical & Biotechnology Companies
  • Cell Banks
  • Contract Service Laboratories
  • Government Agencies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Government Support for Pharma as well as Biotech Industry
      • 3.2.2. Technological Advancement in Mycoplasma Testing
    • 3.3. Market Challenges
      • 3.3.1. Dearth Of Skilled Workforce
    • 3.4. Market Trends
      • 3.4.1. High Demand Due to Cell Culture Contamination
      • 3.4.2. Huge R&D Investments in Life Sciences
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mycoplasma Testing, by Type, Application, Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Mycoplasma Testing (Value)
      • 5.2.1. Global Mycoplasma Testing by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other]
        • 5.2.1.3. Services
      • 5.2.2. Global Mycoplasma Testing by: Application (Value)
        • 5.2.2.1. Cell Line Testing
        • 5.2.2.2. Virus Testing
        • 5.2.2.3. End of Production Cells Testing
        • 5.2.2.4. Others
      • 5.2.3. Global Mycoplasma Testing by: Technology (Value)
        • 5.2.3.1. ELISA (Enzyme-linked Immunosorbent Assay)
        • 5.2.3.2. Microbial Culture Techniques
        • 5.2.3.3. PCR (Polymerase Chain Reaction)
        • 5.2.3.4. Indirect Assay
        • 5.2.3.5. Enzymatic Methods
        • 5.2.3.6. Direct Assay
      • 5.2.4. Global Mycoplasma Testing by: End User (Value)
        • 5.2.4.1. Academic Research Institutions and Organizations
        • 5.2.4.2. Pharmaceutical & Biotechnology Companies
        • 5.2.4.3. Cell Banks
        • 5.2.4.4. Contract Service Laboratories
        • 5.2.4.5. Government Agencies
      • 5.2.5. Global Mycoplasma Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Mycoplasma Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Charles River Laboratories International, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza Group Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. SGS S.A. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. American Type Culture Collection (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bionique Testing Laboratories, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. InvivoGen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PromoCell GmbH (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mycoplasma Testing Sale, by Type, Application, Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Mycoplasma Testing (Value)
      • 7.2.1. Global Mycoplasma Testing by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other]
        • 7.2.1.3. Services
      • 7.2.2. Global Mycoplasma Testing by: Application (Value)
        • 7.2.2.1. Cell Line Testing
        • 7.2.2.2. Virus Testing
        • 7.2.2.3. End of Production Cells Testing
        • 7.2.2.4. Others
      • 7.2.3. Global Mycoplasma Testing by: Technology (Value)
        • 7.2.3.1. ELISA (Enzyme-linked Immunosorbent Assay)
        • 7.2.3.2. Microbial Culture Techniques
        • 7.2.3.3. PCR (Polymerase Chain Reaction)
        • 7.2.3.4. Indirect Assay
        • 7.2.3.5. Enzymatic Methods
        • 7.2.3.6. Direct Assay
      • 7.2.4. Global Mycoplasma Testing by: End User (Value)
        • 7.2.4.1. Academic Research Institutions and Organizations
        • 7.2.4.2. Pharmaceutical & Biotechnology Companies
        • 7.2.4.3. Cell Banks
        • 7.2.4.4. Contract Service Laboratories
        • 7.2.4.5. Government Agencies
      • 7.2.5. Global Mycoplasma Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mycoplasma Testing: by Type(USD Billion)
  • Table 2. Mycoplasma Testing Instruments , by Region USD Billion (2018-2023)
  • Table 3. Mycoplasma Testing Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other] , by Region USD Billion (2018-2023)
  • Table 4. Mycoplasma Testing Services , by Region USD Billion (2018-2023)
  • Table 5. Mycoplasma Testing: by Application(USD Billion)
  • Table 6. Mycoplasma Testing Cell Line Testing , by Region USD Billion (2018-2023)
  • Table 7. Mycoplasma Testing Virus Testing , by Region USD Billion (2018-2023)
  • Table 8. Mycoplasma Testing End of Production Cells Testing , by Region USD Billion (2018-2023)
  • Table 9. Mycoplasma Testing Others , by Region USD Billion (2018-2023)
  • Table 10. Mycoplasma Testing: by Technology(USD Billion)
  • Table 11. Mycoplasma Testing ELISA (Enzyme-linked Immunosorbent Assay) , by Region USD Billion (2018-2023)
  • Table 12. Mycoplasma Testing Microbial Culture Techniques , by Region USD Billion (2018-2023)
  • Table 13. Mycoplasma Testing PCR (Polymerase Chain Reaction) , by Region USD Billion (2018-2023)
  • Table 14. Mycoplasma Testing Indirect Assay , by Region USD Billion (2018-2023)
  • Table 15. Mycoplasma Testing Enzymatic Methods , by Region USD Billion (2018-2023)
  • Table 16. Mycoplasma Testing Direct Assay , by Region USD Billion (2018-2023)
  • Table 17. Mycoplasma Testing: by End User(USD Billion)
  • Table 18. Mycoplasma Testing Academic Research Institutions and Organizations , by Region USD Billion (2018-2023)
  • Table 19. Mycoplasma Testing Pharmaceutical & Biotechnology Companies , by Region USD Billion (2018-2023)
  • Table 20. Mycoplasma Testing Cell Banks , by Region USD Billion (2018-2023)
  • Table 21. Mycoplasma Testing Contract Service Laboratories , by Region USD Billion (2018-2023)
  • Table 22. Mycoplasma Testing Government Agencies , by Region USD Billion (2018-2023)
  • Table 23. South America Mycoplasma Testing, by Country USD Billion (2018-2023)
  • Table 24. South America Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 25. South America Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 26. South America Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 27. South America Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 28. Brazil Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 29. Brazil Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 30. Brazil Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 31. Brazil Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 32. Argentina Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 33. Argentina Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 34. Argentina Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 35. Argentina Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 36. Rest of South America Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 37. Rest of South America Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 38. Rest of South America Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 39. Rest of South America Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 40. Asia Pacific Mycoplasma Testing, by Country USD Billion (2018-2023)
  • Table 41. Asia Pacific Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 42. Asia Pacific Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 43. Asia Pacific Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 44. Asia Pacific Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 45. China Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 46. China Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 47. China Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 48. China Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 49. Japan Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 50. Japan Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 51. Japan Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 52. Japan Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 53. India Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 54. India Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 55. India Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 56. India Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 57. South Korea Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 58. South Korea Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 59. South Korea Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 60. South Korea Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 61. Taiwan Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 62. Taiwan Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 63. Taiwan Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 64. Taiwan Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 65. Australia Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 66. Australia Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 67. Australia Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 68. Australia Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 69. Rest of Asia-Pacific Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 70. Rest of Asia-Pacific Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 71. Rest of Asia-Pacific Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 72. Rest of Asia-Pacific Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 73. Europe Mycoplasma Testing, by Country USD Billion (2018-2023)
  • Table 74. Europe Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 75. Europe Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 76. Europe Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 77. Europe Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 78. Germany Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 79. Germany Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 80. Germany Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 81. Germany Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 82. France Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 83. France Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 84. France Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 85. France Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 86. Italy Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 87. Italy Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 88. Italy Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 89. Italy Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 90. United Kingdom Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 91. United Kingdom Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 92. United Kingdom Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 93. United Kingdom Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 94. Netherlands Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 95. Netherlands Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 96. Netherlands Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 97. Netherlands Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 98. Rest of Europe Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 99. Rest of Europe Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 100. Rest of Europe Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 101. Rest of Europe Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 102. MEA Mycoplasma Testing, by Country USD Billion (2018-2023)
  • Table 103. MEA Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 104. MEA Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 105. MEA Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 106. MEA Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 107. Middle East Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 108. Middle East Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 109. Middle East Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 110. Middle East Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 111. Africa Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 112. Africa Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 113. Africa Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 114. Africa Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 115. North America Mycoplasma Testing, by Country USD Billion (2018-2023)
  • Table 116. North America Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 117. North America Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 118. North America Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 119. North America Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 120. United States Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 121. United States Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 122. United States Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 123. United States Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 124. Canada Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 125. Canada Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 126. Canada Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 127. Canada Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 128. Mexico Mycoplasma Testing, by Type USD Billion (2018-2023)
  • Table 129. Mexico Mycoplasma Testing, by Application USD Billion (2018-2023)
  • Table 130. Mexico Mycoplasma Testing, by Technology USD Billion (2018-2023)
  • Table 131. Mexico Mycoplasma Testing, by End User USD Billion (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Mycoplasma Testing: by Type(USD Billion)
  • Table 143. Mycoplasma Testing Instruments , by Region USD Billion (2025-2030)
  • Table 144. Mycoplasma Testing Kits & Reagents [Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other] , by Region USD Billion (2025-2030)
  • Table 145. Mycoplasma Testing Services , by Region USD Billion (2025-2030)
  • Table 146. Mycoplasma Testing: by Application(USD Billion)
  • Table 147. Mycoplasma Testing Cell Line Testing , by Region USD Billion (2025-2030)
  • Table 148. Mycoplasma Testing Virus Testing , by Region USD Billion (2025-2030)
  • Table 149. Mycoplasma Testing End of Production Cells Testing , by Region USD Billion (2025-2030)
  • Table 150. Mycoplasma Testing Others , by Region USD Billion (2025-2030)
  • Table 151. Mycoplasma Testing: by Technology(USD Billion)
  • Table 152. Mycoplasma Testing ELISA (Enzyme-linked Immunosorbent Assay) , by Region USD Billion (2025-2030)
  • Table 153. Mycoplasma Testing Microbial Culture Techniques , by Region USD Billion (2025-2030)
  • Table 154. Mycoplasma Testing PCR (Polymerase Chain Reaction) , by Region USD Billion (2025-2030)
  • Table 155. Mycoplasma Testing Indirect Assay , by Region USD Billion (2025-2030)
  • Table 156. Mycoplasma Testing Enzymatic Methods , by Region USD Billion (2025-2030)
  • Table 157. Mycoplasma Testing Direct Assay , by Region USD Billion (2025-2030)
  • Table 158. Mycoplasma Testing: by End User(USD Billion)
  • Table 159. Mycoplasma Testing Academic Research Institutions and Organizations , by Region USD Billion (2025-2030)
  • Table 160. Mycoplasma Testing Pharmaceutical & Biotechnology Companies , by Region USD Billion (2025-2030)
  • Table 161. Mycoplasma Testing Cell Banks , by Region USD Billion (2025-2030)
  • Table 162. Mycoplasma Testing Contract Service Laboratories , by Region USD Billion (2025-2030)
  • Table 163. Mycoplasma Testing Government Agencies , by Region USD Billion (2025-2030)
  • Table 164. South America Mycoplasma Testing, by Country USD Billion (2025-2030)
  • Table 165. South America Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 166. South America Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 167. South America Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 168. South America Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 169. Brazil Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 170. Brazil Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 171. Brazil Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 172. Brazil Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 173. Argentina Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 174. Argentina Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 175. Argentina Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 176. Argentina Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 177. Rest of South America Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 178. Rest of South America Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 179. Rest of South America Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 180. Rest of South America Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 181. Asia Pacific Mycoplasma Testing, by Country USD Billion (2025-2030)
  • Table 182. Asia Pacific Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 183. Asia Pacific Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 184. Asia Pacific Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 185. Asia Pacific Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 186. China Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 187. China Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 188. China Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 189. China Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 190. Japan Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 191. Japan Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 192. Japan Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 193. Japan Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 194. India Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 195. India Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 196. India Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 197. India Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 198. South Korea Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 199. South Korea Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 200. South Korea Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 201. South Korea Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 202. Taiwan Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 203. Taiwan Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 204. Taiwan Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 205. Taiwan Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 206. Australia Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 207. Australia Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 208. Australia Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 209. Australia Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 210. Rest of Asia-Pacific Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 211. Rest of Asia-Pacific Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 212. Rest of Asia-Pacific Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 213. Rest of Asia-Pacific Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 214. Europe Mycoplasma Testing, by Country USD Billion (2025-2030)
  • Table 215. Europe Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 216. Europe Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 217. Europe Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 218. Europe Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 219. Germany Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 220. Germany Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 221. Germany Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 222. Germany Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 223. France Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 224. France Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 225. France Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 226. France Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 227. Italy Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 228. Italy Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 229. Italy Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 230. Italy Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 231. United Kingdom Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 232. United Kingdom Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 233. United Kingdom Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 234. United Kingdom Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 235. Netherlands Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 236. Netherlands Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 237. Netherlands Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 238. Netherlands Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 239. Rest of Europe Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 240. Rest of Europe Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 241. Rest of Europe Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 242. Rest of Europe Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 243. MEA Mycoplasma Testing, by Country USD Billion (2025-2030)
  • Table 244. MEA Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 245. MEA Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 246. MEA Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 247. MEA Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 248. Middle East Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 249. Middle East Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 250. Middle East Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 251. Middle East Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 252. Africa Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 253. Africa Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 254. Africa Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 255. Africa Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 256. North America Mycoplasma Testing, by Country USD Billion (2025-2030)
  • Table 257. North America Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 258. North America Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 259. North America Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 260. North America Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 261. United States Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 262. United States Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 263. United States Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 264. United States Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 265. Canada Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 266. Canada Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 267. Canada Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 268. Canada Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 269. Mexico Mycoplasma Testing, by Type USD Billion (2025-2030)
  • Table 270. Mexico Mycoplasma Testing, by Application USD Billion (2025-2030)
  • Table 271. Mexico Mycoplasma Testing, by Technology USD Billion (2025-2030)
  • Table 272. Mexico Mycoplasma Testing, by End User USD Billion (2025-2030)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mycoplasma Testing: by Type USD Billion (2018-2023)
  • Figure 5. Global Mycoplasma Testing: by Application USD Billion (2018-2023)
  • Figure 6. Global Mycoplasma Testing: by Technology USD Billion (2018-2023)
  • Figure 7. Global Mycoplasma Testing: by End User USD Billion (2018-2023)
  • Figure 8. South America Mycoplasma Testing Share (%), by Country
  • Figure 9. Asia Pacific Mycoplasma Testing Share (%), by Country
  • Figure 10. Europe Mycoplasma Testing Share (%), by Country
  • Figure 11. MEA Mycoplasma Testing Share (%), by Country
  • Figure 12. North America Mycoplasma Testing Share (%), by Country
  • Figure 13. Global Mycoplasma Testing share by Players 2023 (%)
  • Figure 14. Global Mycoplasma Testing share by Players (Top 3) 2023(%)
  • Figure 15. Global Mycoplasma Testing share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Charles River Laboratories International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Charles River Laboratories International, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Lonza Group Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Lonza Group Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 23. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 25. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 27. SGS S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. SGS S.A. (Switzerland) Revenue: by Geography 2023
  • Figure 29. American Type Culture Collection (United States) Revenue, Net Income and Gross profit
  • Figure 30. American Type Culture Collection (United States) Revenue: by Geography 2023
  • Figure 31. Bionique Testing Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bionique Testing Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. InvivoGen (United States) Revenue, Net Income and Gross profit
  • Figure 34. InvivoGen (United States) Revenue: by Geography 2023
  • Figure 35. PromoCell GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. PromoCell GmbH (Germany) Revenue: by Geography 2023
  • Figure 37. Global Mycoplasma Testing: by Type USD Billion (2025-2030)
  • Figure 38. Global Mycoplasma Testing: by Application USD Billion (2025-2030)
  • Figure 39. Global Mycoplasma Testing: by Technology USD Billion (2025-2030)
  • Figure 40. Global Mycoplasma Testing: by End User USD Billion (2025-2030)
  • Figure 41. South America Mycoplasma Testing Share (%), by Country
  • Figure 42. Asia Pacific Mycoplasma Testing Share (%), by Country
  • Figure 43. Europe Mycoplasma Testing Share (%), by Country
  • Figure 44. MEA Mycoplasma Testing Share (%), by Country
  • Figure 45. North America Mycoplasma Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific Inc. (United States)
  • Charles River Laboratories International, Inc. (United States)
  • Lonza Group Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Roche Diagnostics (Switzerland)
  • SGS S.A. (Switzerland)
  • American Type Culture Collection (United States)
  • Bionique Testing Laboratories, Inc. (United States)
  • InvivoGen (United States)
  • PromoCell GmbH (Germany)
Additional players considered in the study are as follows:
WuXi AppTec (United States) , Norgen Biotek Corp. (Canada) , Agilent Technologies (United States) , Biotools, B & M Labs, S.A (Spain) , Eurofins Scientific (Luxembourg) , Gibraltar Laboratories (United States) , GeneCopoeia, Inc. (United States) , GenBio (Canada) , Hylabs (Israel) , Minerva Biolabs GmbH (Germany) , Meridian Bioscience, Inc. (United States) , Sartorius AG (Germany) , Savyon Diagnostics (Israel) , ScienCell Research Laboratories, Inc. (Canada)
Select User Access Type

Key Highlights of Report


Apr 2024 217 Pages 66 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mycoplasma Testing Quantitative research analysis
Global Mycoplasma Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Thermo Fisher Scientific Inc. (United States), Charles River Laboratories International, Inc. (United States), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (United States), Bionique Testing Laboratories, Inc. (United States), InvivoGen (United States) and PromoCell GmbH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Demand Due to Cell Culture Contamination " is seen as one of major influencing trends for Mycoplasma Testing Market during projected period 2023-2030.
The Mycoplasma Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Mycoplasma Testing Market to reach USD1.19 Billion by 2030.

Know More About Global Mycoplasma Testing Report?

Have a Query? Click Here

Other Related Reports

Bracing and Supports Comprehensive Study by Type (Knee Braces & Supports, Foot and Ankle Braces & Supports, Spinal Orthoses, Upper Extremity Braces & Supports), Application (Ligament Injury, Preventi...
$ 3650
Endodontics Treatments Comprehensive Study by Type (Root Canal Therapy, Fixing Broken Teeth, Dental Trauma), Application (Hospitals, Dental Clinic, Laboratories, Dental Academic Research Institute), ...
$ 3750
Blood Irradiation Comprehensive Study by Type (X-ray Blood Irradiation, Gamma-ray Blood Irradiation), Application (Patients Inherited Immune System Disorder, Patients with Hodgkin’s Disease, Others),...
$ 3450
Zika Virus Testing Comprehensive Study by Technology (Molecular Test, Serologic Test, Plaque Reduction Neutralization Test (PRNT)), End User (Hospital/Clinic, Diagnostics Laboratory, Academic and Res...
$ 3350
Tooth Gel Comprehensive Study by Type (Organic, Chemically activated), Application (For Brushing Teeth, Whitening Gels, For Toothaches), End Users (Adults, Kids), Distribution channel (Online Shop, S...
$ 3350
Vagal Nerve Stimulators Comprehensive Study by Type (Implantable VNS Device, Non-invasive VNS Device), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression, Anxiety, Other...
$ 3800